Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

Novo Nordisk rebrands to 'Novo' under CEO Mike Doustdar Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it faces stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products. Novo laid out new principles that the company will operate under, including achieving focus and speed through clear priorities and simplified workflows. In this article NVO NVO Follow your favorite stocks CREATE FREE ACCOUNT People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk on Monday said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it has been grappling with stiff competition from chief rival Eli Lilly and investor pressure to deliver new blockbuster products and chart a path toward long-term growth. Novo is preparing to detail its business strategy changes during its Capital Markets Day event on Sept. 21. In a release, Novo also announced a broader company rebrand focused around the phrase "Lasting Health Starts Now," which promotes the idea that patients should make progress toward long-term well-being immediately rather than later. The company said the marketing is a bid to build relevance and trust with the public and other stakeholders, and bring "breakthrough science closer to people's daily lives." Shares of Novo have dropped about 15% this year despite the successful launch of the oral version of Wegovy, which surpassed 3 million prescriptions as of June. The company recently scrapped three trials on an experimental cardiovascular drug. That challenge came as it continues to lag in the obesity space with 38.8% market share compared to Lilly's 60.9% in the second quarter, according to a Lilly earnings presentation citing IQVIA data. Novo Nordisk will remain the legal name for the company, according to the release. That original name dates back to the 1989 merger of two competing Danish pharmaceutical companies: Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium. The drugmaker said its corporate culture will be based on a new set of four principles that will help it gain advantages in an increasingly competitive market where more of its products have gone direct-to-consumer. Those tenets are innovating with patients as the primary focus, raising the company's performance to "create greater value for all stakeholders," setting clearer priorities and simpler workflows and never compromising on patient safety and ethics. Despite its challenges, Novo has had one significant tailwind this year in the launch of the oral version of Wegovy. On top of its explosive launch, the pill had a head start over a rival weight loss pill from Lilly called Foundayo. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.